Cargando…

Competing endogenous RNA network in newly diagnosed multiple myeloma by genetic microarray

Detalles Bibliográficos
Autores principales:	He, Yu-Qin, Zhang, Zhi-Yao, Zhou, Hui-Xing, Ye, Fang, Chen, Wen-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Clinical Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722612/ https://www.ncbi.nlm.nih.gov/pubmed/32991370 http://dx.doi.org/10.1097/CM9.0000000000001108

Ejemplares similares

Is t(11;14)(q13;q32) good or bad for newly diagnosed multiple myeloma?
por: Liu, Yang, et al.
Publicado: (2023)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
por: Zheng, Yong-Zhi, et al.
Publicado: (2021)

Percutaneous vertebroplasty combined with chemotherapy in the treatment of multiple myeloma patients with vertebral compression fractures
por: Zhang, Yang, et al.
Publicado: (2022)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Induction Therapy and Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2012)

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2022)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
por: Rijneveld, Anita W., et al.
Publicado: (2022)

Clinical and histopathological analyses of anaplastic myeloma
por: Huang, Jun-Xia, et al.
Publicado: (2020)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients
por: Bao, Li, et al.
Publicado: (2020)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
por: Peres, Lauren C., et al.
Publicado: (2022)

More intensive therapy has a better effect for frail parents with multiple myeloma
por: DuMontier, Clark, et al.
Publicado: (2023)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma
por: Li, Ying, et al.
Publicado: (2016)

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)
por: Varshavsky Yanovsky, A., et al.
Publicado: (2023)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2madgtv09rjej40ndq461ioq2i